Search results
Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure
Benzinga via Yahoo Finance· 11 months agoIn its ongoing R&D reorganization, Biogen Inc (NASDAQ: BIIB) will discontinue a Phase 3 program...
Blood test measuring DNA damage may help diagnose Parkinson's disease
United Press International via Yahoo News· 8 months agoA new blood test that measures DNA damage in the mitochondria of cells may help diagnose Parkinson's...
A Big New Parkinson’s Drug Just Passed a Crucial Safety Trial
The Daily Beast via Yahoo News· 2 years agoKateryna Kon / Science Photo Library via GettyThere are currently no FDA-approved means to prevent...
Biogen (BIIB) to End One of Two Parkinson's Studies on BIIB122
Zacks via Yahoo Finance· 11 months agoBiogen (BIIB) is now set to focus on the LUMA study on its and partner Denali Therapeutics' (DNLI)...
Biogen (BIIB), Denali Begin Mid-Stage Study on Parkinson's Drug
Zacks via Yahoo Finance· 2 years agoBiogen (BIIB) and partner Denali initiate a mid-stage study to evaluate their oral LRRK2 inhibitor,...
Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More
Zacks via Yahoo Finance· 11 months agoIt was a busy week for the biotech sector, with loads of data presentations at the 2023 American...
Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues
Zacks via Yahoo Finance· 9 months agoDenali Therapeutics DNLI delivered earnings of $1.30 per share for second-quarter 2023 on higher...
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
Zacks via Yahoo Finance· 1 month agoA month has gone by since the last earnings report for Denali Therapeutics Inc. (DNLI). Shares have...
QIAGEN (QGEN) to Develop Companion Diagnostic for Neuron23
Zacks via Yahoo Finance· 2 years agoQIAGEN's (QGEN) novel companion diagnostic assay will help identify individuals who might benefit...
Denali (DNLI) Lags Q3 Earnings Estimates, Pipeline in Focus
Zacks via Yahoo Finance· 2 years agoDenali Therapeutics DNLI incurred a loss of 84 cents per share for third-quarter 2022, wider than...